Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03182725 · ClinicalTrials.gov registry record · Phase 3
Effect of Ivabradine on Patients With Postural Orthostatic Tachycardia Syndrome
A Phase 3 study of Postural Orthostatic Tachycardia Syndrome, sponsored by University of California, San Diego.
- Completed
- Registry status
- Phase 3
- Development phase
- 37
- Enrollment target
- 1
- Study location
NCT03182725: Completed Phase 3 study of Postural Orthostatic Tachycardia Syndrome, sponsored by University of California, San Diego.
NCT03182725 is a Phase 3 study of Postural Orthostatic Tachycardia Syndrome that has completed, run by University of California, San Diego. The registered enrollment target is 37 participants, below the 9,241-participant average among 11 other Postural Orthostatic Tachycardia Syndrome trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03182725, a Phase 3 study of Postural Orthostatic Tachycardia Syndrome, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 37 participants
- Enrollment target
- 1
- Study location
Study Summary
Postural orthostatic tachycardia syndrome (POTS) occurs in approximately 500,000 Americans, but predominates in women with a 5:1 ratio. Patients with POTS experience debilitating tachycardia upon postural changes such as standing that impairs their quality of life. Tachycardia is clinically defined as a heart rate greater than 100 beats/min; and in POTS patients, the prolonged heart rate increase is greater than 30 beats/min or increases to 120 beats/min within the first ten minutes of a diagnostic tilt table test without postural hypotension. There are currently no effective treatment methods for POTS. However, several studies suggest Ivabradine could be a main treatment option for POTS because Ivabradine specifically inhibits the f-channels (If) within the sinoatrial (SA) node, which slows the heart rate. Currently in the US, Ivabradine is mainly prescribed to treat chronic heart failure. It is well tolerated in patients, but it is not commonly prescribed for POTS. It has been also used for treatment of inappropriate sinus tachycardia with good benefit. The hypothesis for this experiment is that Ivabradine will reduce tachycardia and improve functional status in patients with POTS.
Primary Outcome
Orthostatic heart rate monitoring will be used to gauge heart rate changes.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ivabradine
Study Locations (1)
California
- University of California, San Diego - La Jolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2018-02-06 |
| Est. Completion | 2020-05-08 |
| Phase | Phase 3 |
What the finished NCT03182725 record still lists
NCT03182725 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 9,241-participant average among 11 other Postural Orthostatic Tachycardia Syndrome trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Postural Orthostatic Tachycardia Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03182725 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03182725 about?
NCT03182725 is a clinical study titled "Effect of Ivabradine on Patients With Postural Orthostatic Tachycardia Syndrome". Postural orthostatic tachycardia syndrome (POTS) occurs in approximately 500,000 Americans, but predominates in women with a 5:1 ratio. Patients with POTS experience debilitating tachycardia upon postural changes such as standing that impairs their quality of life. Tachycardia is clinically defined ...
What is the current status of trial NCT03182725?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 37 participants. The study started on 2018-02-06. Estimated completion is 2020-05-08.
What conditions does trial NCT03182725 study?
This clinical trial studies the following conditions: Postural Orthostatic Tachycardia Syndrome.
What interventions are being tested in trial NCT03182725?
The interventions under investigation include: Placebo (DRUG), Ivabradine (DRUG).
Who is sponsoring clinical trial NCT03182725?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03182725 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Postural Orthostatic Tachycardia Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03182725's enrollment target sits among peer trials
37 10th of 11 higher than 2 of 11 other Postural Orthostatic Tachycardia Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Postural Orthostatic Tachycardia Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Auricular Vagal Nerve Stimulation for Hypermobile Ehlers-Danlos Syndrome
RECRUITING · NA
-
The Long COVID-19 Wearable Device Study
RECRUITING · NA
-
Phenotyping of Postural Orthostatic Tachycardia Syndrome (POTS)
RECRUITING
-
Assessment of Antibodies and Inflammatory Markers in Postural Tachycardia Syndrome
ACTIVE NOT RECRUITING
-
Evaluating the Prevalence of Acute Hepatic Porphyria in Postural Tachycardia Syndrome
ACTIVE NOT RECRUITING
-
Pathophysiology of Orthostatic Intolerance
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI